Lina Li | Senior Manager, Investor Relations |
John Leonard | President and Chief Executive Officer |
Laura Sepp-Lorenzino | Executive Vice President and Chief Scientific Officer |
Glenn Goddard | Executive Vice President and Chief Financial Officer |
Andrew Schiermeier | Executive Vice President and Chief Operating Officer |
José Rivera | Executive Vice President, General Counsel and Corporate Secretary |
Gena Wang | Barclays |
Maury Raycroft | Jefferies |
David Nierengarten | Wedbush Securities |
Amanda Murphy | BTIG Capital |
Steven Seedhouse | Raymond James |
Madhu Kumar | Robert W. Baird & Co |
Silvan Tuerkcan | Oppenheimer |
Tashdid Hasa | ROTH Capital Partners |
Good morning. My name is Derrick, and I will be your conference operator today and welcome to the Intellia Therapeutics’ Third Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Following the formal remarks, we will open the call for your questions. Please be advised that this call is being recorded at the company's request.